Endophthalmitis following intravitreal injections

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 4, 2012, Pages 499-505

  Irigoyen, Cristina ^a,b   Ziahosseini, Kimia ^a   Morphis, George ^a   Stappler, Theodor ^a   Heimann, Heinrich ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

AntiVEGF; Endophthalmitis; Intravitreal injections; Intravitreal triamcinolone

Indexed keywords

BEVACIZUMAB; CIPROFLOXACIN; CIPROXEN; RANIBIZUMAB; TEICOPLANIN; TRIAMCINOLONE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; BACTERIUM CULTURE; CLINICAL ARTICLE; ENDOPHTHALMITIS; EYE PAIN; FEMALE; GLAUCOMA; GRAM NEGATIVE BACTERIUM; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; VISUAL ACUITY; VITRECTOMY; AQUEOUS HUMOR; ARTICLE; BACTERIAL EYE INFECTION; BACTERIUM; DRUG ANTAGONISM; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; TREATMENT OUTCOME; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; BACTERIA; CIPROFLOXACIN; COMBINED MODALITY THERAPY; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEICOPLANIN; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 84861321251     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1851-1     Document Type: Review

References (28)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med 351:2805-2816
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age related macular degeneration. N Engl J Med 355:1419-1431
3. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, FOCUS Study Group (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532-1542
4. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
5. Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups (2007) The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 144:454-456
6. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518-522
7. Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S (2008) Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115:1911-1915
8. Ness T, Feltgen N, Agostini H, Böhringer D, Lubrich B (2010) Toxic vitreitis outbreak after intravitreal injection. Retina 30:332-338
9. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, Oyagi T, Sawada K (2010) Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 117:512-516
10. Roth DB, Flynn HW Jr (2008) Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 146:346-347
11. Jonas JB, Spandau UH, Schlichtenbrede F (2008) Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 22:590-591
12. Endophthalmitis Vitrectomy Study Group (1995) Results of the Endophthalmitis Vitrectomy Study: A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 113:1479-1496
13. Kuhn F, Gini G (2005) Ten years after are findings of the Endophthalmitis Vitrectomy Study still relevant today? Graefes Arch Clin Exp Ophthalmol 243:1197-1199
14. The Royal College of Ophthalmologists; Guidelines for Intravitreal Injections Procedure 2009
15. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509-516
16. Greenwood D (1988) Microbiological properties of teicoplanin. J Antimicrob Chemother 21(Suppl A):1-13
17. Chisari G (2008) Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides. Curr Clin Pharmacol 3:153-155
18. Avery RL, Fekrat S, Hawkins BS, Bressler NM (1996) Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16:183-189
19. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A (2010) Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 30:1051-1057
20. Schwartz SG, Flynn HW, Scott IU (2009) Endophthalmitis after intravitreal injections. Expert Opin Pharmacother 10:2119-2126
21. Sampat KM, Garg SJ (2010) Complications of intravitreal injections. Curr Opin Ophthalmol 21:178-183
22. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M (2008) Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 145:879-882
23. Akçakaya AA, Sargin F, Erbil HH, Yazici S, Yaylali SA, Mesçi C, Ergin S, Midilli K (2011) A cluster of acute-onset postoperative endophthalmitis over a 1-month period: investigation of an outbreak caused by uncommon species. Br J Ophthalmol 95:481-484
24. Komori S, Sawada A, Oguni T, Mochizuki K, Ohkusu K (2010) Case of endophthalmitis following intravitreal injections of bevacizumab. Clin Ophthalmol 4:773-775
25. Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA (2010) Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 25:519-524
26. Moshfeghi AA, Rosenfeld PJ, Flynn HW, Schwartz SG, Davis JL, Murray TG, Smiddy WE, Berrocal AM, Dubovy SR, Lee WH, Albini TA, Lalwani GA, Kovach JL, Puliafito CA (2011) Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six year experience at a University Referral Center. Retina 31:662-668
27. McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31:654-661
28. The Endophthalmitis Vitrectomy Study Group (1996) Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol 122:830-846